Empagliflozin Patent Expiration

Empagliflozin is Used for reducing cardiovascular risk and treating type 2 diabetes, heart failure, and chronic kidney disease with empagliflozin. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc in its drug Jardiance on Aug 1, 2014. 2 different companies have introduced drugs containing Empagliflozin.


Empagliflozin Patents

Given below is the list of patents protecting Empagliflozin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Jardiance US10258637 Pharmaceutical composition, methods for treating and uses thereof Apr 03, 2034 Boehringer Ingelheim
Jardiance US10258637

(Pediatric)

Pharmaceutical composition, methods for treating and uses thereof Oct 03, 2034 Boehringer Ingelheim
Jardiance US10406172 Pharmaceutical composition, methods for treating and uses thereof Jun 15, 2030 Boehringer Ingelheim
Jardiance US11090323 Pharmaceutical composition, methods for treating and uses thereof Apr 03, 2034 Boehringer Ingelheim
Jardiance US11090323

(Pediatric)

Pharmaceutical composition, methods for treating and uses thereof Oct 03, 2034 Boehringer Ingelheim
Jardiance US11666590 Pharmaceutical composition, methods for treating and uses thereof Apr 03, 2034 Boehringer Ingelheim
Jardiance US11813275 Pharmaceutical composition, methods for treating and uses thereof Apr 03, 2034 Boehringer Ingelheim
Jardiance US11833166 Pharmaceutical composition, methods for treating and uses thereof Apr 03, 2034 Boehringer Ingelheim
Jardiance US7579449 Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture Aug 01, 2028 Boehringer Ingelheim
Jardiance US7579449

(Pediatric)

Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture Feb 01, 2029 Boehringer Ingelheim
Jardiance US7713938 Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments Apr 15, 2027 Boehringer Ingelheim
Jardiance US7713938

(Pediatric)

Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments Oct 15, 2027 Boehringer Ingelheim
Jardiance US8551957 Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate Oct 14, 2029 Boehringer Ingelheim
Jardiance US8551957

(Pediatric)

Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate Apr 14, 2030 Boehringer Ingelheim
Jardiance US9949997 Pharmaceutical composition, methods for treating and uses thereof May 17, 2034 Boehringer Ingelheim
Jardiance US9949997

(Pediatric)

Pharmaceutical composition, methods for treating and uses thereof Nov 17, 2034 Boehringer Ingelheim
Jardiance US9949998 Pharmaceutical composition, methods for treating and uses thereof Jun 11, 2034 Boehringer Ingelheim
Jardiance US9949998

(Pediatric)

Pharmaceutical composition, methods for treating and uses thereof Dec 11, 2034 Boehringer Ingelheim


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳

Empagliflozin Generics

Several generic applications have been filed for Empagliflozin.

Given below is the list of companies who have filed for Empagliflozin generic.


1. ZYDUS PHARMS

Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Empagliflozin. Given below are the details of the strengths of this generic introduced by Zydus Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG tablet Discontinued ORAL N/A Aug 3, 2022
25MG tablet Discontinued ORAL N/A Aug 3, 2022